Park National Corp OH Boosts Stake in Zoetis Inc. $ZTS

Park National Corp OH increased its stake in Zoetis Inc. (NYSE:ZTS) by 16.3% during the first quarter, Holdings Channel.com reports. The firm owned 100,435 shares of the company’s stock after purchasing an additional 14,108 shares during the quarter. Park National Corp OH’s holdings in Zoetis were worth $11,872,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the period. State Street Corp lifted its position in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after buying an additional 189,235 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Zoetis during the 4th quarter valued at approximately $734,425,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
• Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
• Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Insider Buying and Selling at Zoetis

In related news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 in the last three months. 0.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. Stifel Nicolaus reduced their target price on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Citigroup reduced their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $133.92.

Zoetis Stock Performance

NYSE ZTS opened at $78.69 on Friday. The firm has a market cap of $32.99 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 1.23 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business has a 50-day moving average price of $93.01 and a 200-day moving average price of $112.54. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $161.77.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.